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Olleedyen. The purpose otthis study was m determine whether
0 low procedural activated coagulation time In assocaled with a
high rate of 6boepikl complication and to Idndty whether
thaw is n atirettd coagalotiou line raises that may be
associated
with a low role of complications .
Bartgroud.
In recent yeas the activated coagulation tote has
come bib widespread me far menltmag andnagwletion In the
c Bum laboratory. However. considerable controversy
cadre; m to the standards by width to judge •• adequate•• nadco-
agase" for bahwentlnal pocedmes .
Medkdr, From a Mid of 1,469 ensamive patients with
paathmtm tromloalml coronary angioplty, we retroapea
lively idaifed 103 (Group 1, 7% of the overall population) with
adjust eoaplkalkm of death or emergency m urgent canary
artery bypass graft surgery ad compared them with 400 patients
without co mpBcolum (Group M . Group I patients had more high
clot dkleal ehaemkrWim, such n type B and C leslom, alms III
ad IV Millions, ream-nyowdW infraction and recent throutho-
171k trgamL Activated coagulation times was compared be.
Widespread application of interventional procedures per-
formed in the cardiac catheterization laboratory has led to
recognition of the importance of adequate anticoagulation.
It has been customary to administer a large (10 .000 to
15,000 U) bolus dose of Imparin before percutaneous tans-
lumind coronary angioplasty ad. in some cases, to
start a
continuous heparin infusion if the procedure time is pro .
longed, The activated coagulation time is a rapid assay of
whole-blood clotting that has become part of the routine
assessment of anticoagulation and heparin reversal in pa-
tients undergoing cardiopulmonary bypass surgery (1-9). In
recent years, this test has also become part of the manage-
ment of patients undergoing interventional procedures in the
catheterization laboratory (10-14) .
However, considerable controversy remains as to the
exact standards by which to judge "adequate" anticongula-
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twee., Grasp- I and II at Mnlke, alter tahninistrstko of
10,000 U of heproia and at da and at the procedure.
Results . There were ae dlfanaos In haselge activated coag .
ukdou times between Groups I and U
. Group I bad eigaileauuy ,
lower activated coagulation tbees after hepnk therapy and m the
end or the procedure : 61% <250 s. 20% between 250 and 275 a,
11% between 275 and 300 a and 8% >300 a; 279 of Group U had
activated eeagahdon tams 27% <250 s, 17% between 250 and
275 s, 35% between 275 and 300 a had 21% >300 a (p < 0.0001).
Complications occurred k in pink" with And activated cow
louses times <250 s but k only 0.3% of patients with find
titivated coagulation dam >300 s.
Conclusions
. A dYinlthed activated coagdation time response
to an initial bolus of hpak is associated with major 61mapkell
complications after coronary angleplmty, although patients with
complications did have a higher risk before the procedure . H
remains to be determined whether thus is an ideal
"
target"
activated ewagulWou date for hltervndaal procedures .
(J Am Call (74091 IM;23
.,
1061-5)
Lion for interventional procedures . The cardiopulmonary
bypass surgery data cannot be extrapolated to patients
undergoing Coronary angioplasty, especially given the use of
the newer amomuted coagulation timers. There are two
automated coagulatimrtimerscurrentlyinclioicaluse ; Homo-
chron (International Technidyne Corporation) and HemoTec
(Medtronic HemoTec). Most of the published studies to date
using automated activated coagulation time measurements in
patients with coronary angioplasty have used the Homo-
chron coagulation timer. There are few published dam on the
HemoTec coagulation timer for coronary angioplasty
(12 .13).
The purpose of the present study was to determine
whether low procedural HemoTec activated coagulation
times are associated with a high rate of subsequent in-
hospital complications and
to identify whether there may be
a range of procedural activated coagulation time measure-
ments that is associated with a low rate of complications .
Methods
In the 12-month period between October 1988 and Octo-
ber 1989
. there were 1,469 coronary angioplasty procedures
0735 .109799157.01)
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Table 1 . Patient Chancreristics for Groups I and 11
Values preswld an men slue s SD "number dentists
. CABG -
summary awry bypass pall suraery.
performed at St. Luke's Episcopal Hospital . We retrospec-
lvely identified all 103 patients (7%) in Ibis group with major
in-hospital complications of death (II patients) and emer-
gency (75 patients) and urgent (same day) (17 patients)
coronary artery bypass surgery
. The patients with major
complications (Group I) were compared with 400 patients
with successful coronary angioplasty from the same time
period (Group II). Group 11 patients comprised the first 40D
patients in our patient data base of the original cohort of
1,469 patients with no procedural complications who had
activated coagulation times measured at baseline, after hep-
arin therapy and at the end of the procedure .
As part of the normal routine in the catheterization
laboratory, activated coagulation times were measured in all
patients at baseline, before any heparin was administered .
Patients then routinely received an intravenous bolus of
10,000 U of heparin, and activated coagulation time was
again measured at least 5 min after the heparin bolus . All
blood samples were drawn through the arterial sheath . All
activated coagulation time measurements were performed
with use of a HemoTec coagulation timer and high range
cartridges with kaolin activator
. Them cartridges are de-
signed to give a response of -10D s far every I Uhel of
heparin . Duplicate samples were ran, and the awaits of the
two samples were averaged to provide a final value .
During the course of the subsequent coronary angioplasty
procedure. additional heparin was administered, and addi-
lioml procedural activated coagulation times were checked
at the discretion of the operator . A final activated cagda-
lion time was measured at the end of the procedure, just
before the patient left the catheleriration laboratory .
The following activated coagulation times were measured
or calculated in each patient : baseline, after heparin therapy,
at
the end tithe procedure (final activated coagulation time)
and activated coagulation time heparin response (defined as
the activated coagulation time after heparin therapy minus
the baseline activated coagulation time) . Measurements
were compared between Groups I and 11 by a two-sample r
test and by chi-square analysis . Measurements were com•
pared between patients with and without complications at
different activated coagulation time levels by chi-square
analysis, and p < 0.05 was considered significant .
Table S. Clinical Characteristics of Patinas in Groups I
andH
'p
a
0.0p07Grsep 1 mama Gmep It. 9p a 0.0.9 Group I -maw Creep II.
Vases prewotrd re Same value a SD or number I3) or patterns. MI -
myocudii Wanctiao: NYHA - Ner Yak
Head Anomalies
; PICA -
prMauous )rammi ul caemay aegoplWy.
Resells
The demographic characteristics of Groups I (major com-
plications) and H (no major complications) (Table 1) were
not
significantly
different between the two groups
. However
.
there were clinical differences between both groups, as
shown in Table 2. Group 11 patients had more type A and
fewer type C lesions anti were mom often in New York
Hear Association functional classes 11 and W . with fewer
patients in elm IV. In Group I there were more patients
with a recent myocardial infarction who had undergone
recent thrombolysis amt mole patients on a hope& drip
before coronary angioplasty. Group I patients had also
received significantly less procedural hapuin than Group II
patients.
Activated coagulation times m baseline, after heparin
therapy, and at the end of the procedure In Groups I and 11
are shown In Table 3. There was no significant deference in
baseline activated coagulation times between the two
groups. but activated coagulation times after hapuin deeeapy
and at the end of the procedure were
significantly
lower In
Group 1, u was the activated coagulation time heparin
response. Activated coagulation time values for each of the
three major complications are also limed in Table 3 .
Table 4 shows the uwnber of patients in Groups I and lI
with and without complications at four different activated
coagulation time levels after heparin therapy . Of 171 patients
in both groups with activated coagulation times <250 s after
heparin therapy, 63 (representing 37% of the 171 patients at
that activated cagulatmt time level, or 61 .2% of all Group
I patients) had major complications, and 108 (representing
63% of the 171 patients at that activated coagulation time
level, or 27%
of
all Group II patients) did not . 01 `243 patients
in both groups with activated coagulation times >275 a after
GtwpI
(complications)
to
=103)
amp 11
loo co olirliasl
In-4m1
Lesontype-
A 413.9%) 42(10.7%)
a
50(41.5%1
274(40.5%)
C 49)47.6%) 04(21%1
NYHA amceolw
elms-
1
0)0%) 4(1 .0%)
11 211.9%) 42(10.5%)
In 30)29.1%) 134(33
.5%1
IV 71(oz) 2m 139%)
Racer MI
(e30days)'
211794%1 26
(6!%1
Raced
thimholyalu'
15 114-6151
17(41%)
Total proem hepulell doe 13.7
± 4 4
17 .8213
(14ur
Hepaiu drip berore PICAS 31)29%1 75 )10.7%)
Total
No. men women
Am
(yr)
Group I
Urpeot CABG 17 IS 2 602 10
Fmagr,cy CARD
7
55
m
59 ± 7
Durh
11 9
2 61 1
13
Teal 103 79
24 59 ± 10
Group 11 40a 7m 92 37 ± 11
IACIC Vat. 23,14.. 5
Apa 1996:10615
Ta61e 3. Activated Coagulation Times for Groups I and 11
'p a 0.0001 Group I versus Group 11, Va!0es prrenisl ae mron ,clue - SD w number or *=ft. ALT -
aclivaed oaguld .lime. CAHG = wruooe an,- 1,W., Frill surgery .
heparin therapy. 19 (representing l of the 243 patients at
that activated coagulation time level . or 18
.4% of all Group
I patients) had complications, and 2_24 (representing 92% of
the 243 patients at that activated coagulation time level . or
56% of all Group 11 patients) did not . The differences
between groups were significant (p < 0.000I).
Table 5 shows the number of patients in Groups I and 11
with and without complications at four different final acti-
vated coagulation lime levels
. A') 97 patients with final
activated coagulation times <250 s had complications. Only
three (0.8%) of 379 patients with final activated coagulation
times 2275 s had complications, and only one 10.3%) of 317
patients with a final activated coagulation time ?300 s had
complications. The differences between groups were signif-
icant (P < 0.000)) .
Table 6 shows the number of patients in Groups I and It
with and w(thout complications al four differ it heparin
response levels. Of 333 patients in both groups who in-
cmsed their activated coagulation times by < ISO s after a
103700-U hepn of heparin . 87 (representing 26%
of the 333
patients at that activated coagulation time level, or 84
.5% or
all Gimp I patients) had complications . Of 95 patients in
both groups who increased their activated coagulation time
by >175 s after a 10
.000-U bolus of hepol in, 3 (representing
3% of the 95 patients at that activated coagulation lime level,
or 2.9% of all Group I patients) had complications. The
difereacea between groups were significant (p < 0 .0001) .
Dlac,aa91W1
pranat Ydy. We documented that low procedural actl-
vated coagulation tunes are associated with a higher rate of
In-hospital complications alter coronary angioplasty. Our
Table 4. Activated
Coagulation Times Attar Heparin Therapy
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ACT V ATFn rnannl ATION TIME AND oerrroMn AFT2n rttA
data suggest that the risk of cunlplicalihms (urgent and emer-
gency surgery . death) are substantially increased in patients
with activated coagulation times <250 s after heparin then
a2y or at the end of the procedure and in patients with an
activated coagulation time response to 10,000 U of
heparin
<L515 s. Conversely, patients with activated coagulation
times >275 s after heparin therapy or at the end of the
procedure or an activated coagulation time response to
10,1010 U of heparin > 175 A had very few complications,
All of our measurements were performed with a Hemo-
Tee automated coagulation timer, which uses a totally dif-
ferent measurement technique from the Hemochron system
.
the other commercially available automated coagulation
timer
. The results of these two different systems are not in
any way comparable
. and a target activated coagulation time
of 3110 s rat tine machine is not the same as a target activated
coagulation time of 300 s on the other (15) .
Interpremaan of results. One factor to consider in inter-
pteting our results is that there was individual variation
among physicians in our institution with regard to manage-
ment of patients. aggressiveness with which procedural
anticoagulation was approached and selection of patients for
bypass surgery
. The complications in Group I may be solely
attributed to their higher incidence of clinical
risk factors,
many of which are associated with new or recent coronary
thrombosis . The diminished activated coagulation time re-
sponse in Group I may be a secondary phenomenon, and, in
the face of lower procedural heparin doses, it cannot be
concluded that the complications were related only to the
lower activated coagulation time . The complications in these
patients may have resulted from their high risk profile and a
low final activated coagulation time as a result
of less
procedural heparin
.
p < O.Oml by cbiagsare analysi . Pen=s ruler l0 total
amber of patiens is Group I or Group II. ACT =
anivaed
.Sub
5-c. rice.
Tout
No.
MO. .
ACC Isl
ACT After lie*.
Tnrr, .py ref
Foul
ACT Ist
ACT Heroic
Rrgonre Is)
Grasp I
Urgent CASG 17 117 a 16 22
'x36
212x13 106x37
E -F.7 CAOG
:5
121 0 1s L 22x27 73 x 35
Mall, 11 117 - 20 214 : 2: 226 : 32 93 x 39
TOM 101 110 x 39 229 c 35' 232 a 21' 110 x 39'
Group 11
as 119 - 21 _59'_ 45 303 *_ 25 140 ± 43
ACT After Hetmin'IMopy Isl
<SO 250_275 275-300
aNn
Group I
Implications) G 161 .134) 21 420.4%) II 110
.7',31 6(7 .7n)
Group It l.oaogolioeioesl 108127%)
0411531 140)33%)
94131311
Total
171 m 151
93
1064
	
FERGUSON ET AL.
ACTIVATED COAGULATION TIME AND OUTCOME AFTER PTG
Table 5. Final Activated Coagulation Times for Groups I and U•
Q50
Group I (romptia0mm) 07 (805%)
Group
n
(so wmplic.bo,ie) 0
N%)
Total 67
b < 0.0001 by chi-mom analysis. ACT
-
corroded wraulanop
With the widespread application of activated coagulation
times in our catheterization laboratory, there were changes
in the practice pattern of physicians performing interven-
tional procedures in our institution as they began to rely
more heavily on activated coagulation time measurements
for the proper guidance of anticaagulatou. The time period
of the present study (1988 to 1989) was early in our experi,
once, and we did not rely as heavily on activated coagulation
trees as we do now .
In interpreting these results it is also important to remem-
bar that this is A retrospective study. We compared a group
with complications with a randomly selected subgroup of
patients from the same time period without complications.
Because of this approach, the absolute percent of compiica-
dons at any given activated coagulation lime level or at any
given response to an initial dose of heparin may be lower,
but the trends exhibited In our data should still be valid . We
did not evaluate procedural activated coagulation
times
after
subsequent heparin boluses (other than the find activated
coagulation time), so we cannot directly extrapolate our
results to the concept of an activated coagulation time
"threshold" or "target."
In addition, the final activated coagulation time Measure-
ments may reflect events that transpired in the caheteriza-
tion laboratory, which, In turn, may have resulted In adverse
events as well as in affecting the total dose of heparin
administered. We noted a number of circumstances where
abrupt vessel closure in the emheterkation laboratory is
accompanied by a precipitous decrease in activated cagu-
laton time . Low final activated coagulation time may
reflect an ongoing thrombotic process (perhaps initiated by
in-laboratory
complications)
or inadequate beporklizallon,
or both . The activated coagulation time after heparin therapy
and the activated coagulation time response to an initial
bolus of heparin are associated with complications after
coronary angioplasty
. However, a low activated coagulation
flout ACT (s)
250-273 275--lm >300
13 (ra.6%1 2f).9%) I(1%)
24(5%) 60(15%) 316)10%)
37 62 317
Table 6. Activated Coagulation Time heparin Response Values for Groups I and 11•
time after heparin therapy and a diminished heparin Te-
sponse may also reflect antecedent dinical events, and rather
than being an independent risk factor, mad heparin re-
sponse may be a secandary manifestation of the underlying
CH" s m.
Urinated gaWlou. We have not answered the ques-
tion of whether the aol coag la ion
s
tatus. as expressed in
the activated coagulation time, is a primary or secondary
cause of in-hospital complications . Do patients have compl-
catons because their activated coagulation times arc low, or
are their activated coagulation times low because they have
complications? Is there truly an activated coagulation throe
threshold that signifies "adequate" anticoagulation? Again,
the answer to these questions will regime prospective
studies. In our own laboratory, however, we have adopted a
fairly aggesuive approach to anticoagulation. Moat opera-
tors in our laboratories will attempt to achieve a HemTec
activated coagulation time of at keen 275 to 300 a. Ore data
suggest that an association exists between in-hospital core-
pliation and a low activated coagulation time after heparin
therapy (<250 a). a low heparin response (<150 a) and a low
final activated coagulation time (<250 a) . Conversely, there
appears to be as association between freedom has compf-
atons and a high activated coagulation time alter heparin
therapy (>275 a), a high heparin response (>175 s) and a
high 110111 activated Coagulation time (>775 8). Whether them
associations can be predictive on en individual basis will
require further prospective Study-
Previous cardiopulmonary bypass data (1,2) cited by
other investigators in support of a 'target" activated coag.
elation time range of 300 s were obtained using a manual
system for measuring activated coagulation times (16). not
with either of the commercial automated systems . Previous
studies (12) have also suggested that a 10,000.13 bolus dose
of heparin provides "adequate" anticoagulation (a target
activated coagulation time arbitrarily defined as 300 a using a
	p
< 0.0901 by cld•tgtme sodyea. Penal, war to teal matter or pstreats is Grwp I wOr up D . ACT =
aaivaad cosauluion dam
.
IACC Val. 23, No. S
Aid 1994:1061
ACT Heparin Response (eh
<13D 130-173 175.200 >200
Group I (csmpS lines) 07 (4.3)l) 1302 .0%) 2(l .9%) 1(1%)
(].up II (no canpacadom) 246(61 .9%) 63(13 .35) 4000161 32(13%)
total 333 75 42 53
JACC Vol. 23 . No. 5
April 199eua6W
Hemochron machine) in 89% ofpatients:11% ofpatients will
require additional5eparia. Previous data (13) using a Hemo-
Tee machine instead of a Hemcchron machine suggest that
the percent of patients achieving "adequate"
anticoagula-
tion
is much lower. Only 13% of patients had an activated
coagulation time >300 S atera 10,000•U bolus of aepatin . In
the present study,
34% of the total group of patients had an
activated coagulation time <250 s : 19% had an activated
coagulation time between 250 and 275 s; 30% had an acti•
vated coagulation lime between 275 and 300 s; and I S%
had
an activated coagulation time of >300 s. There are currently
so real
standards to date for determining what is truly
"adequate - anticoagulation.
Conclusions. I) There are no differences in baseline acti-
vated coagulation times between patients with and without
major in-hospital complications after coronary angioplasty .
Z) A diminished activated coagulation time response
to
heparin Is
associated with major in-hospital complications
after coronary angioplasty, although patients with complica-
tions did have higher prepeoceduro risk
. 3)11 remains to be
determined prospectively whether there is a threshold acti-
vated coagulation lime level that, if achieved during an
intervemional procedure, would reduce the risk of
major
complications.
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